Literature DB >> 23823478

TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress.

Haiyoung Jung1, Mi Jeong Kim, Dong Oh Kim, Won Sam Kim, Sung-Jin Yoon, Young-Jun Park, Suk Ran Yoon, Tae-Don Kim, Hyun-Woo Suh, Sohyun Yun, Jeong-Ki Min, Hee Gu Lee, Young Ho Lee, Hee-Jun Na, Dong Chul Lee, Hyoung-Chin Kim, Inpyo Choi.   

Abstract

Reactive oxygen species (ROS) are critical determinants of the fate of hematopoietic stem cells (HSCs) and hematopoiesis. Thioredoxin-interacting protein (TXNIP), which is induced by oxidative stress, is a known regulator of intracellular ROS. Txnip(-/-) old mice exhibited elevated ROS levels in hematopoietic cells and showed a reduction in hematopoietic cell population. Loss of TXNIP led to a dramatic reduction of mouse survival under oxidative stress. TXNIP directly regulated p53 protein by interfering with p53- mouse double minute 2 (MDM2) interactions and increasing p53 transcriptional activity. Txnip(-/-) mice showed downregulation of the antioxidant genes induced by p53. Introduction of TXNIP or p53 into Txnip(-/-) bone marrow cells rescued the HSC frequency and greatly increased survival in mice following oxidative stress. Overall, these data indicate that TXNIP is a regulator of p53 and plays a pivotal role in the maintenance of the hematopoietic cells by regulating intracellular ROS during oxidative stress.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23823478     DOI: 10.1016/j.cmet.2013.06.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  50 in total

Review 1.  Nutrient Sensing and the Oxidative Stress Response.

Authors:  Hanzhi Luo; Hou-Hsien Chiang; Makensie Louw; Albert Susanto; Danica Chen
Journal:  Trends Endocrinol Metab       Date:  2017-03-15       Impact factor: 12.015

2.  Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.

Authors:  Alicia Báez; Beatriz Martín-Antonio; José I Piruat; Concepción Prats; Isabel Álvarez-Laderas; M Victoria Barbado; Magdalena Carmona; Álvaro Urbano-Ispizua; Jose Antonio Pérez-Simón
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

3.  6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.

Authors:  Yanning Liu; Guohua Lou; John T Norton; Chen Wang; Irawati Kandela; Shuai Tang; Nathaniel I Shank; Pankaj Gupta; Min Huang; Michael J Avram; Richard Green; Andrew Mazar; Daniel Appella; Zhi Chen; Sui Huang
Journal:  FASEB J       Date:  2017-08-17       Impact factor: 5.191

4.  K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains.

Authors:  Fumiaki Ohtake; Hikaru Tsuchiya; Yasushi Saeki; Keiji Tanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

5.  Phospho-proteomic discovery of novel signal transducers including thioredoxin-interacting protein as mediators of erythropoietin-dependent human erythropoiesis.

Authors:  Matthew A Held; Emily Greenfest-Allen; Edward Jachimowicz; Christian J Stoeckert; Matthew P Stokes; Antony W Wood; Don M Wojchowski
Journal:  Exp Hematol       Date:  2020-04-04       Impact factor: 3.084

Review 6.  The Dual Role of ROS in Hematological Malignancies: Stem Cell Protection and Cancer Cell Metastasis.

Authors:  Azin Samimi; Mohammad Javad Khodayar; Hadis Alidadi; Elahe Khodadi
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 7.  Stem cells and the impact of ROS signaling.

Authors:  Carolina L Bigarella; Raymond Liang; Saghi Ghaffari
Journal:  Development       Date:  2014-11       Impact factor: 6.868

Review 8.  Hematopoietic stem cell niche maintenance during homeostasis and regeneration.

Authors:  Avital Mendelson; Paul S Frenette
Journal:  Nat Med       Date:  2014-08       Impact factor: 53.440

9.  Ex vivo human HSC expansion requires coordination of cellular reprogramming with mitochondrial remodeling and p53 activation.

Authors:  Luena Papa; Eran Zimran; Mansour Djedaini; Yongchao Ge; Umut Ozbek; Robert Sebra; Stuart C Sealfon; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-10-23

Review 10.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.